Related Experiment Video
Updated: Oct 25, 2025

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis
Published on: November 4, 2017
Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease
Carles Gaig1, Yaroslau Compta2, Anna Heidbreder2
1From the Neuroimmunology Program (C. Gaig, L.S., A.I., J.S.C., J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Department of Neurology (C. Gaig, Y. Compta, M.J.M., A.I., J.S., J.D.), Multidisciplinary Sleep Disorders Unit (C. Gaig, A.I., J.S.), and Parkinson's Disease & Movement Disorders Unit (Y. Compta, M.J.M.), Hospital Clinic, Barcelona, Spain; Department of Neurology, Division of Sleep Medicine and Neuromuscular Disorders (A.H.), University Hospital Muenster, Germany; Department of Neurology (A.H., B.H.), Medical University of Innsbruck, Austria; Department of Neurology (M.J.T., Y. Crijnen), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Neurology (J.L.), Ulm University, Germany; Neurology Department, Complejo Hospitalario de Navarra (M.E.E.), Navarra Institute for Health Research (IdiSNA), Pamplona; Neurology Department (J.C.G.-M.), Hospital Universitario de Basurto, Bilbao (formerly Department of Neurology, Hospital de Galdakao); Movement Disorders Center (P.N., N. Tambasco), Perugia General Hospital and University of Perugia, Italy; Department of Neurology and Neurorehabilitation (M.P.-O.), Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland; Department of Neurology (M.E.), Klinik Donaustadt, Karl-Landsteiner-Institut, Vienna; Division of Neuropathology and Neurochemistry (R.H.), Department of Neurology (S.M., E.B.-S.), Medical University of Vienna, Austria; Section Translational Neuroimmunology (C. Geis), Department of Neurology, Jena University Hospital, Germany; Department of Neurology 1 (M.H.), Neuromed Campus, Kepler Universitätsklinikum Linz; Department of Neurology with Stroke Unit and Acute Geriatrics (M.H.), Saint John of God Hospital Linz, Austria; Department of Neurology and Neurosciences (A.M.-T., A.M.-B.), Clínica Universidad de Navarra, Pamplona-Madrid; Department of Neurology (L.L., S.Q.), Hospital La Princesa, Madrid, Spain; Department of Neurology (G.U.H., N.M.), Hannover Medical School; Department of Neurology (F.S.) and Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center (F.S.T.), Ludwig-Maximilians-University, Munich, Germany; Department of Biomedical and NeuroMotor Sciences (DiBiNeM) (G.M.A., F.P.), Alma Mater Studiorum University of Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (F.P.); Department of Biomedical, Metabolic and Neural Sciences (G.P.), University of Modena and Reggio Emilia, Modena; IRCCS (G.P.), Institute of Neurological Sciences of Bologna, Italy; Neurology Department (K.B.), Cruces University Hospital, Barakaldo, Spain; Department of Neurology (M.B.), Odense University Hospital, Denmark; Department of Neurology and Institute of Neurogenetics (N.B.), University of Lübeck, Germany; Department of Neurology (T.F.), Medical Clinic of Hospital Geral Cleriston Andrade, Feira de Santana, Brazil; Neurology Unit, Department of Medicine (C.F.N.), Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia; Department of Movement Disorders and Neurology (C. Giordana), CHU Nice, France; Department of Neurology (A.H.-S.M.), Hospital Universitario 12 de Octubre, Madrid, Spain; Department of Psychobiology (L.H.), Universidade Federal de São Paulo, Brazil; Clinical Neurosciences (K.K.), St Vincent's Hospital, Melbourne, Australia; Department of Neurology (H.L.), LKH Murtal, Standort Knittelfeld, Austria; Department of Neurology (T.M.), Fundación Jiménez Diaz, Madrid; Department of Neurology (C.M.), Hospital Universitari i Politècnic La Fe, Valencia; Department of Neurology (J.P.P.), Hospital de la Santa Creu i Sant Pau, Barcelona; Department of Neurology (I.P.), Hospital La Paz, Madrid, Spain; Department of Neurology (T.S.-H.), Medical University of Graz, Austria; Department of Neurology (C.S.), Mainz University Hospital, Mainz, Germany; Department of Neurology (M.M.S.), University of São Paulo Medical School, Brazil; Department of Neurology (N. Tellez), Hospital Clínico Universitario, Valladolid; Department of Neurology (J.V.-Á.), Hospital Universitario Rey Juan Carlos, Madrid, Spain; Department of Neurology (B.W.), Antwerp University Hospital and University of Antwerp, Belgium; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain. cgaig@clinic.cat francesc.graus@idibaps.org.
Background And Objectives:
Anti-IgLON5 disease is a recently described neurologic disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are underreported. We describe the frequency and types of movement disorders in a series of consecutive patients with this disease.
Methods:
In this retrospective, observational study, the presence and phenomenology of movement disorders were assessed with a standardized clinical questionnaire. Available videos were centrally reviewed by 3 experts in movement disorders.
Results:
Seventy-two patients were included. In 41 (57%), the main reason for initial consultation was difficulty walking along with one or several concurrent movement disorders. At the time of anti-IgLON5 diagnosis, 63 (87%) patients had at least 1 movement disorder with a median of 3 per patient. The most frequent abnormal movements were gait and balance disturbances (52 patients [72%]), chorea (24 [33%]), bradykinesia (20 [28%]), dystonia (19 [26%]), abnormal body postures or rigidity (18 [25%]), and tremor (15 [21%]). Other hyperkinetic movements (myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias) occurred in 26 (36%) patients. The craniofacial region was one of the most frequently affected by multiple concurrent movement disorders (23 patients [32%]) including dystonia (13), myorhythmia (6), chorea (4), or myokymia (4). Considering any body region, the most frequent combination of multiple movement disorders consisted of gait instability or ataxia associated with craniofacial dyskinesias or generalized chorea observed in 31 (43%) patients. In addition to abnormal movements, 87% of patients had sleep alterations, 74% bulbar dysfunction, and 53% cognitive impairment. Fifty-five (76%) patients were treated with immunotherapy, resulting in important and sustained improvement of the movement disorders in only 7 (13%) cases.
Discussion:
Movement disorders are a frequent and leading cause of initial neurologic consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment.
More Related Videos
Related Concept Videos
Parkinson's Disease: Overview
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Positive Symptoms of Schizophrenia: Hallucinations and Delusions
Thought Disorders
Disorganized and unusual thought processes mark thought disorders in schizophrenia. One key feature is disorganized speech, where an individual's conversation includes...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

